Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.
Half of all cancer patients fail chemotherapy. This resistance increases mortality and represents a major burden for the health care system.
With approximately 18 million new cancer cases being diagnosed each year, a new treatment that can help overcome chemotherapy resistance could have immense business potential.
Scandion Oncology is working to develop treatments that will re-sensitize cancer cells to chemotherapy within metastatic colon and breast cancer.
We believe Scandion Oncology’s approach could help improve outcomes for thousands of cancer patients, creating substantial business potential.
– Nils Brünner, CEO
Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.
Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning two Phase II trials within metastatic colorectal cancer and metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.
Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.